REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicentre, single-arm, Phase IV Itolizumab Trial: RESURRECT

KR Raveendra, Chirag Rathod, Rahul Darnule, Subramanian Loganathan, Sarika Deodhar, A Radhika, Ashwani Marwah, Nitin M Chaudhari, Binay K Thakur, Sivakumar Vaidyanathan, Sandeep Nilkanth Athalye
doi: https://doi.org/10.1101/2021.10.25.21265462

Article usage

Article usage: October 2021 to June 2025

AbstractFullPdf
Oct 20217516115
Nov 202134715101
Dec 2021214651
Jan 20222121425
Feb 2022136319
Mar 2022961115
Apr 202283518
May 202275518
Jun 202273517
Jul 202255410
Aug 202274910
Sep 202254318
Oct 202250414
Nov 202245515
Dec 202247620
Jan 202344718
Feb 20232836
Mar 20232828
Apr 20233729
May 20232427
Jun 20231954
Jul 20232054
Aug 202334137
Sep 20232968
Oct 20231815
Nov 202327611
Dec 20232244
Jan 20241333
Feb 20241887
Mar 202420117
Apr 202419813
May 202429010
Jun 20241447
Jul 202416213
Aug 20241635
Sep 202429810
Oct 202413106
Nov 202421213
Dec 2024236103
Jan 202524627
Feb 20251987
Mar 2025413015
Apr 202526320
May 202523419
Jun 2025935
Back to top
Posted October 28, 2021.
Download PDF

Supplementary Material

Data/Code
Email
REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicentre, single-arm, Phase IV Itolizumab Trial: RESURRECT
KR Raveendra, Chirag Rathod, Rahul Darnule, Subramanian Loganathan, Sarika Deodhar, A Radhika, Ashwani Marwah, Nitin M Chaudhari, Binay K Thakur, Sivakumar Vaidyanathan, Sandeep Nilkanth Athalye
medRxiv 2021.10.25.21265462; doi: https://doi.org/10.1101/2021.10.25.21265462
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area